The incidence of venous thromboembolic events in clinical trials was similar in patients receiving Avastin in combination with chemotherapy compared to those receiving the control chemotherapy alone.
Kliinilistes uuringutes oli venoossete trombemboolsete seisundite esinemissagedus sarnane Avastin’ i kombinatsioonis kemoteraapiaga ja ainult kemoteraapiat saanud patsientidel.